



**Not to be released before 5. November 2004**

## **PAION and Philips Announce Use of Philips Groundbreaking Brain Perfusion CT Software in PAION's Desmoteplase Drug Trial**

AACHEN, GERMANY AND CLEVELAND, OH – 5 November, 2004 – PAION and Philips have announced that Philips groundbreaking brain perfusion CT software package will be used in conjunction with PAION's further clinical trials for its investigational drug Desmoteplase.

PAION has chosen the Philips-exclusive software to assist in the determination of safety and effectiveness of Desmoteplase in the treatment of stroke patients. The software displays summary maps, which make it possible to distinguish between still-viable and non-viable infarcted tissue and includes quantitative color maps of cerebral blood flow, cerebral blood volume, mean transit time and time-to-peak. These provide valuable clinical information for treatment planning and assisting clinicians in making reasonably accurate predictions as to which individual patients may benefit from reperfusion therapy.

*"Philips provides a cutting edge imaging technology that is urgently needed to speed up patient diagnosis. We are excited to have Philips support in this first stroke drug trial where patients are included after a perfusion CT diagnosis,"* said the CEO of PAION, Dr. Wolfgang Söhngen.

*"This collaboration aims to deliver simple, yet dynamic new methods for effectively caring for stroke patients,"* said Jim Green, senior vice president and general manager, CT, for Philips Medical Systems. *"We think the perfusion CT exam will speed up and, yet, simplify the time-critical assessment and diagnosis of stroke patients, which should help clinicians to quickly develop key insights for more confident decisions on appropriate treatments, such as Desmoteplase."*

### **About Philips Brain Perfusion CT Software and Stroke Imaging**

Philips Brain Perfusion CT Software is a post-processing software that assists the user to distinguish between the core of an infarction, or the dead tissue, and the

ischaemic penumbra, or the viable but insufficiently perfused tissue. It was developed by Philips based on technology developed by Dr. Max Wintermark and a research team at the Hospices/CHUV, university hospital in Lausanne in Switzerland.

### **About Desmoteplase and Stroke**

Desmoteplase, first in a new class of plasminogen activators, is a genetically engineered version of a clot-dissolving protein found in the saliva of the vampire bat *Desmodus rotundus*. Earlier this year, PAION presented positive results from a Phase II trial demonstrating the compound's potential to treat patients up to nine hours after the onset of stroke symptoms. Desmoteplase will be developed and marketed in North America by Forest Laboratories, Inc. and was recently granted fast track status by the US Food and Drug Administration.

Stroke is the third leading cause of death in Europe and the United States, after heart disease and cancer. The treatment of acute stroke and related serious long-term disabilities currently present an enormous unmet medical need. The only drug currently approved for the intravenous treatment of acute ischaemic stroke must be administered within three hours of the onset of stroke symptoms, which limits the potential patient population that can safely benefit from the rapid dissolution of the blood clot and the restoration of blood flow to the affected area of the brain.

### **About Royal Philips Electronics**

Royal Philips Electronics of the Netherlands (NYSE: PHG, AEX: PHI) is one of the world's biggest electronics companies and Europe's largest, with sales of \$32.8 billion (EUR 29 billion) in 2003. With activities in the three interlocking domains of healthcare, lifestyle and technology and 165,600 employees in more than 60 countries, it has market leadership positions in medical diagnostic imaging and patient monitoring, color television sets, electric shavers, lighting and silicon system solutions. News from Philips is located at [www.philips.com/newscenter](http://www.philips.com/newscenter).

### **About PAION**

PAION AG, a biopharmaceutical company based in Aachen, Germany, aims to become a leading provider of innovative drugs for the treatment of stroke and other thrombotic diseases for which there is a substantial unmet medical need. With its core competence in advancing purchased or in-licensed drug candidates

through the clinical development and regulatory approval process, PAION believes it is ideally equipped to achieve this goal. The company's most advanced drug candidate, Desmoteplase, has recently received fast track status from the US Food and Drug Administration. PAION currently employs approximately 50 people and has raised EUR 51.2 million in four equity financing rounds since its foundation in 2000. More information at: [www.paion.de](http://www.paion.de).

## **Contacts**

PAION  
Birgit Jansen  
Tel: +49 241 44 53 150  
[b.jansen@paion.de](mailto:b.jansen@paion.de)

Philips  
Heidi Wilson, Philips  
Tel: +1 978 659 7302  
[heidi.wilson@philips.com](mailto:heidi.wilson@philips.com)

Philips  
Steve Kelly, Philips  
Tel: +1 425 487 7479  
[Steve.Kelly@philips.com](mailto:Steve.Kelly@philips.com)